BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Osteoporosis readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Osteoporosis\, from C
 linicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04608630-3268@assetmemo.bio
DTSTAMP:20261122T012610Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Denosumab (Prolia): Phase 2 readout est. (NCT04608630)
DESCRIPTION:Denosumab (Prolia)\, phase 2\, Osteoporosis.\nStudy: Bone Loss 
 Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults\nEst
 imated primary completion: 28 February 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/denosumab-prolia#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04608630
URL:https://assetmemo.bio/drug/denosumab-prolia#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04800367-3268@assetmemo.bio
DTSTAMP:20261122T012610Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Denosumab (Prolia): Phase 2 readout est. (NCT04800367)
DESCRIPTION:Denosumab (Prolia)\, phase 2\, Osteoporosis.\nStudy: Romosozuma
 b/Denosumab Study for Premenopausal IOP\nEstimated primary completion: Mar
 ch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/denosumab-pr
 olia#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04800367
URL:https://assetmemo.bio/drug/denosumab-prolia#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
